The lysates were subjected to immunoprecipitation using anti-Flag beads. IP and pull-down efficiency were detected using anti-Flag or anti-Myc antibodies.
(B) Endogenous SRSF3 and SRSF10 were immunoprecipitated with exogenously expressed SFB-YTHDC1. The lysate of 293T cells transfected with SFB-YTHDC1 was incubated with streptavidin sepharose beads to immunoprecipitate SFB-YTHDC1 and its interacting partners. The blots were detected with indicated antibodies.
(C) Exogenously expressed SFB-YTHDC1 could not immunoprecipitate other endogenous splicing regulators including SF1, PTBP1, ELAVL1, SRSF2, SRSF11 and hnRNP G.
(D) In-vitro pull-down assay using purified Myc-YTHDC1 and Flag-hnRNP C failed to show direct interaction between these two proteins.
(E) Coomassie brilliant blue staining of purified full length, N-and C-terminus of different epitope tagged proteins. 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES Plasmid Construction and Protein Expression
Total RNA extracted from 293T cells using Trizol Reagent (Life Technologies) was used for cDNA synthesis by
Reverse Transcription PCR using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) and oligo ( YTHDC1 double-mutant (DM: W377A and W428A) was generated by introducing point mutations using
QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene) using pCMV-Myc-YTHDC1-WT plasmid as template. YTHDC1-WT-siYTHDC1 insensitive (WT-Ins), YTHDC1-DM-siYTHDC1 insensitive (DM-Ins) were also generated by introducing point mutations using QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene) using pCMV-Myc-YTHDC1-WT and pCMV-Myc-YTHDC1-DM plasmids as template, respectively. These mutants were also subcloned into pEGFP-C1 vector for rescue immunofluorescence assay.
Plasmid constructs were verified by sequencing. All the primers used for cloning are enlisted in the following table.
Primers Sequence Information for Plasmid Cloning and Site-mutagenesis
Plasmid constructs Primer Sequence
Human SRSF1, SRSF3, SRSF7 and SRSF9 plasmids were bought from OriGene Technologies (Rockville, MD) and their expression constructs were generated using PCR and subcloned into pCS2+ vector with an N-terminal Flag tag (Fu et al., 2013) . Human SRSF10 plasmid (pENTER-Flag-SRSF10) was bought from Vigene Biosciences (CH894033).
To generate the splicing minigene constructs, we amplified ZNF638 genomic fragments covering 500 nt intronic nucleotides up-and downstream of the Exon 2 by PCR using total genomic DNA from HeLa cells and inserted them into the pSpliceExpress reporter vector (addgene) as previously reported (Kishore et al., 2008) .
Using this constructed pSpliceExpress-ZNF638 as template we generated YTHDC1/SRSF3/SRSF10 binding sites mutated pSpliceExpress-ZNF638 by point mutation using QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies). All the primers used for this assay are enlisted in the following table.
Minigene Construction and Mutation Primers
Primers name Sequence
All plasmids were validated by DNA sequencing, and prepared with NucleoBond Xtra Midi plasmid purification kit (Machery Nagel).
Cell Culture, Plasmid and siRNA Transfection
HeLa and 293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Shanghai ExCell Biology Inc.) and 0.5% penicillin/streptomycin (Sigma) at 37C in a humidified incubator with 5% CO 2 .
Plasmid and Polyethylenimine, PEI (Polysciences) were used in the ratio of 3 μl PEI per 1 μg plasmid.
Plasmid and PEI were mixed in serum-and antibiotic-free DMEM separately and incubated for 5 min at room temperature. The plasmid and PEI mixtures were then mixed together and incubated for 15 min at room temperature and added to the cultured cells. After 6 hr the medium of the culture was replaced with complete DMEM.
All the siRNA duplexes used in this study were designed and synthesized by GenePharma, China. The siRNA duplexes were transfected into cells at a final concentration of 50 nM using Rfect siRNA Transfection Reagent Trypsin at 37°C overnight, and further digestion was stopped by adding 1% TFA (trifluoroacetate). Samples thus obtained were subjected to analysis by Q Exactive mass spectrometer (Thermo Fisher Scientific). Peptides were loaded onto a pre-column (75 μm ID packed to 8 cm with 10 μm-C18 resin) and separated on an analytical 75 μm ID column packed to 11 cm with 3 μm-C18 resin (pre-column: ODS-AQ 12 nM S-10 μm (YMC Co., LTD.), analytical column: Luna 3 μm 100 Å resin (Phenomenex)) with an acetonitrile gradient from 0% to 25% in 1 hr and 25% to 80% in another 7 min at a flow rate of 200 nl per min. Spectra were acquired in a data-dependent mode: the 10 most intense ions of +2, +3, or +4 charge from each full scan (R = 70,000) were isolated for HCD MS2 (R = 17,500) at NEC 27 with a dynamic exclusion time of 150 s. For peptide identification, the MS2 spectra were searched against SwissProt human database (forward + reversed sequences) using 15 ppm peptide mass tolerance and 20 mmu fragment mass tolerance. The data files have been uploaded to http://www.peptideatlas.org with the access number: PASS00296.
Protein Purification
293T cells were transfected with Flag-tagged plasmid constructs and after 36 hr harvested with lysis buffer (20 mM Tris-HCl pH 7.4, 500 mM NaCl, 1% NP-40, 1 × Protease inhibitor cocktail) followed by sonication on ice using a Sonic Dismembrator (Fisher Scientific) (10-15 cycles with 10 s pulse-on and 20 s pulse-off, 10% amplitude). After centrifugation at 14,000 rpm for 20 min, the supernatant was filtered using 0.2 m syringe filter (Acrodisc Syringe filters) and the clear lysate was incubated with anti-Flag M2 Affinity Gel (Sigma) by gently rotating for 4 hr at 4°C. The beads were then washed twice with Lysis buffer and twice with TBS (20 mM Tris-HCl pH 7.4, 150 mM NaCl) and incubated with 3 × Flag-Peptide (Sigma) by gently rotating for 1 hr at 4°C to elute the bound proteins. The elution was done twice to maximize the recovery. The protein thus purified was condensed using VIVASPIN 500 (Sartorius Stedim Biotech).
Protein Interaction Assays

Co-Immunoprecipitation (co-IP)
293T cells were co-transfected with indicated plasmids and harvested with lysis buffer (150 mM NaCl, 20 mM Tris-HCl pH 7.4, 0.5% NP-40, 1 mM Na 3 VO 4 , 1 mM glycerophosphate, 1 mM NaF and 1 × Protease inhibitor Cocktail) followed by sonication on ice (10-15 cycles with 10 s pulse-on and 20 s pulse-off, 10% amplitude).
After centrifugation at 14,000 rpm for 20 min the supernatant was incubated with RNase A (1 mg/ml) (Sigma)
by gently rotating for 30 min at room temperature and supernatant was cleared by centrifuging at 14000 rpm for 15 min. The supernatant was incubated with anti-Flag or anti-Myc beads for 3 hr in a moving rotor at 4C, washed three times with lysis buffer and boiled in 2 × SDS loading buffer. The immunoprecipitates were resolved on SDS-PAGE gel and transferred onto PVDF membrane (EMD Millipore) followed by immunoblotting with respective antibodies as indicated. and fluorescent images were acquired using Leica TCS SP8 confocal microscope. The relative mean fluorescence densities were analyzed using ImageJ 1.46 and plotted using GraphPad Prism 6 software. For colocalization detection of two proteins, cells on coverslips were incubated with a mixture of differently sourced (mouse or rabbit) primary antibodies against the two proteins followed by subsequent incubation with a mixture of Cy3 or FITC conjugated anti-mouse or anti-rabbit secondary antibodies. The changes in intensities of co-localization signals were shown by the line scan graph of fluorescence intensity using LAS AF Lite (Leica Microsystems) as described in Loo et al., 2014; Parkinson et al., 2014. For the rescue immunofluorescence assay, HeLa cells grown on coverslips were first transfected with 100 nM siRNA targeting YTHDC1 (siYTHDC1) using RFect siRNA transfection reagent (BIO-TRAN). After 24 hr, the cells were then co-transfected with 100 nM of siYTHDC1 and 2 μg of GFP, GFP tagged siYTHDC1 insensitive wild-type or m 6 A binding defective double-mutant YTHDC1 using Lipofectamine 2000 (Invitrogen). 24 hr after transfection, immunofluorescence staining was performed as described above as indicated. 
In-vitro Protein Pulldown Assay
RNA Isolation, cDNA Synthesis and Semi-quantitative PCR
AS PCR Primers Information
Primers name Sequence
SP4-Exon 2-forward 5'-ACCTCTGAGCCAGAGAATAAC-3'
SP4-Exon 4-reverse 5'-CCTTCTCCTTCCCTACAATTAG-3'
ZNF638-Exon 1-forward 5'-AGCTCTTTGGAGGCGGTAG-3' 
ZNF638-Exon
RNA-seq
HeLa cells were treated with YTHDC1, SRSF1, SRSF3, SRSF7, SRSF9, SRSF10 or control siRNAs for 48 hr and total RNAs were isolated using RNAzol (Molecular Research Center, Inc., USA). High purity mRNAs were enriched from total RNAs using Dynabeads® mRNA purification kit (Ambion). RNAs were fragmented into ~100 nt fragments by 1 min incubation at 94°C in fragmentation buffer (10 mM ZnCl 2 , 10 mM Tris-HCl pH 7.0).
The fragmentation reaction was stopped with 0.05 M EDTA (Ambion), followed by standard ethanol precipitation and collected for sequencing and expression validation. For the RNA-seq, fragmented RNAs were re-suspended in H 2 O and used for cDNA library generation with TruSeq RNA Sample Prep Kit (Illumina)
protocol. All samples were sequenced by Illumina HiSeq 2000 with single or end 101-bp read length. Raw RNA-seq reads were mapped to the human reference genome (version hg19) using TopHat (version 2.0.9) (Trapnell et al., 2009) . Only unique mapped reads with mapping quality more than or equal to 20 were kept for the subsequent analysis for each sample. The number of reads mapped to each Ensembl gene (release 72) was counted using the HTSeq python package (Anders et al., 2015) , with the 'union' overlap resolution mode, and -stranded = no and the expressions of transcripts were quantified as Reads Per Kilobase of exon model per
Million mapped reads (RPKM).
Alternative Splicing Analysis
Percent spliced in (PSI) estimation method applied in previous study was used to analyze alternative splicing events based on RNA-seq data (Mele et al., 2015) . As previously reported , information on intron-exon structures was extracted from Ensembl annotations (release 72) for human (version hg19) genomes.
Then, a BWA (v0.6.2) (Li and Durbin, 2009 ) library of non-redundant EEJ sequences was generated by combining every case (forward combination) of splicing donor and acceptor within each gene. RNA-seq reads were then mapped to the EEJ libraries. Next, the outputs were parsed to identify cassette alternative exons (i.e.
exons that are either included or excluded from the transcripts) by identifying exons that have associated reads mapping to ( donor and acceptor at least were used for PSI calculating and only alternative splicing events supported by a sufficient number of reads, C1A + AC2 + C1C2 >= 10, were considered.
Cassette exons with |ΔPSI| >= 10% in HeLa cells upon depletion of YTHDC1, SRSF3 or SRSF10 compared to control are considered with significant AS events. Besides, public RNA-seq data with METTL3 knockdown (Alarcon et al., 2015; Ping et al., 2014) were downloaded from GEO to investigate whether the AS change of downstream exons were also included) with inclusion events and that with skipping events, where H0 hypothesis means that there is no significant difference of ΔPSIs between these two groups.
PAR-CLIP Assay
PAR-CLIP-seq and PAR-CLIP-biotin chemiluminescent nucleic acid detection were performed as follows. In brief, human HeLa cells with specific gene knockdown and plasmids overexpression were cultured in medium supplemented with 200 μM 4-thio-uridine (4SU) (Sigma, T4509) for 14 hr, and then irradiated once with 400 mJ/cm 2 at 365 nm using the UV crosslinker BLX-E365 (Vilber) to induce crosslinking. Cells were collected and lysed in 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 2 mM EDTA, 0.5% (v/v) NP-40, 1 mM NaF, 1  Protease Inhibitor Cocktail (Sigma, P8340), 0.04 U/ml RNasin (Promega, N251B), and rotated at 4°C for 30 min. Cell debris was removed by centrifugation and the soluble fractions (3-4 mg/ml) were digested by 1 U/μl RNase T1 at 22°C in a water bath for 15 min and cooled on ice for 5 min. Then the soluble fractions were incubated with anti-Flag M2 magnetic beads (Sigma, M8823) or Pierce TM anti-Myc magnetic beads (Thermo, 88843) for about 300 mM NaCl, 0.05% (v/v) NP-40, 1  Protease Inhibitor Cocktail (Sigma, P8340), 0.04 U/ml RNasin (Promega, N251B)). The above obtained samples were digested with 10 U/μl RNase T1 again at 22°C in a water bath for 15 min, cooled on ice for 5 min. Beads were washed three times in high salt wash buffer (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.05% (v/v) NP-40, 1  Protease inhibitor cocktail (Sigma, P8340), 0.04 U/ml RNasin (Promega, N251B)) with 5 min rotation. Protein-RNA-beads mixture were re-suspended in 100 μl dephosphorylation buffer (50 mM Tris-HCl pH 7.9, 100 mM NaCl, 10 mM MgCl2) and incubated with 0.5 U/μl calf intestinal alkaline phosphatase (CIAP, NEB, M0290L) for 10 min at 37°C. The beads were then washed twice with phosphatase wash buffer (50 mM Tris-HCl pH 7.5, 20 mM EGTA, 0.5% (v/v) Triton X-100).
For PAR-CLIP-biotin chemiluminescent nucleic acid detection, protein-RNA complex was labeled with biotin by RNA 3 End Biotinylation kit (Thermo, 20160) following the manufacturer's instructions. Then the beads were washed three times with IP wash buffer (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 0.05% (v/v) NP-40, 1  Protease Inhibitor Cocktail (Sigma, P8340ein complex, and then transferred to PVDF membrane, detected by chemiluminescent nucleic acid detection module (Thermo, 89880) following the manufacturer's instructions.
One fourth of the sample was separated by SDS-PAGE to detect protein immunoprecipitation complex, and then transferred to PVDF membrane, detected by chemiluminescent nucleic acid detection module (Thermo, 89880) following the manufacturer's instructions. One tenth and one fourth of the samples were separated by SDS-PAGE to detect protein immunoprecipitation efficiency and m 6 A level respectively.
For PAR-CLIP-seq, protein-RNA complex was washed twice with PNK buffer (50 mM Tris-HCl pH 7.5, 50
mM NaCl, 10 mM MgCl 2 ), incubated with 1 mM ATP and 1 U/μl T4 PNK (NEB, M0201L) in one original bead volume for 1 hr at 37°C followed by three times washing with PNK buffer (50 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 mM MgCl 2 ). Then the protein-RNA mixture were re-suspended in 30 μl 4  SDS loading buffer (Invitrogen, NP0007) and 90 μl 1  SDS loading buffer (Invitrogen, NP0007), boiled at 95°C for 10 min. Then the sample was separated by SDS-PAGE, transferred to PVDF membrane. The membrane were cut into small piece and digested by 4 μg/μl proteinase K (Roche, 03115828001) in 200 μl PK buffer (100 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 mM EDTA) for 20 min at 37°C following 200 μl PK-urea buffer (100 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 mM EDTA, 7 M urea) incubation for 20 min at 37°C. RNA were followed by three times washing and precipitated in ethanol with the help of glycogen (Thermo, R0551). RNAs in ethanol were sent for the small RNA library construction and deep sequencing. The UHPLC-MS/MS analysis was performed with an Agilent 1290 UHPLC system coupled with a G6410B triple quadrupole mass spectrometer (Agilent Technologies, Palo Alto, CA). A CAPCELL PAK C18 column (100 mm × 2.1 mm I.D., 3 µm particle size, SHISEIDO) was used for UHPLC separation of mononucleotides.
UHPLC separation was used as: 0-6.5 min, 5.0% B; 6.6-11.0min, 20.0% B; 11.1-16.0 min, 100% B; 16.1-24 min, 5.0% B. Solvent A was an aqueous solution of 0.1% formic acid, and solvent B was 100% methanol. The mass spectrometer was operated in the positive ion mode. A multiple reaction monitoring (MRM) mode was adopted:
m/z 282→150 for m 6 A (collision energy, 15 eV), m/z 268→136 for A (10 eV). The injection volume for each sample was 5 µL, and the amount of m 6 A and A was calibrated by standards curves. Nitrogen was used for nebulizing and desolvation gas of MS detection. The nebulization gas was set at 40 psi, the flow-rate of desolvation gas was 9 L/min, and the source temperature was set at 300°C. Capillary voltage was set at 3500 V.
High purity nitrogen (99.999%) was used as collision gas. Each sample was analyzed at least three times.
In-vitro RNA Pulldown Assay
In-vitro RNA pulldown assay was carried out as previously described (Dominissini et al., 2012; Wang et al., 2014) . Briefly, 10 pmol of biotin labeled nucleic acid probes with or without m 
Minigene Splicing Assay
For minigene splicing analysis, 5 μg of wild-type or YTHDC1/SRSF3/SRSF10 binding sites mutated pSpliceExpress-ZNF638 Exon 2 was either transfected into HeLa cells or co-transfected with control or YTHDC1/SRSF3/SRSF10 siRNAs into HeLa cells using Lipofectamine (Invitrogen) after 1 st round siRNAs knockdown, respectively. Forty-eight hours after transfection, total RNA was extracted and reverse transcription PCR was carried out to get the cDNA. Thus obtained cDNA was used as template for AS change detection. All the primers used for this assay are enlisted in the Table S4 .
PAR-CLIP Data Analysis
The PAR-CLIP-seq reads of the YTHDC1 (combining ours and public available data with access number GSE58352) and SRSF proteins were stripped of the adaptor sequence with the Cutadapt software (version 1.2.1) (Martin, 2011) . Reads that were less than 18 nt in length or contained an ambiguous nucleotide were discarded by Trimmomatic (version 0.30) (Bolger et al., 2014) . The remained reads were aligned to the human genome (version hg19), with up to two mismatches allowed, by the Bowtie algorithm (Langmead, 2010) . Mapped locations were only reported for those with the minimum number of observed mismatches for each read. Clusters were obtained by PARalyzer (v1.1) with the default parameters (Corcoran et al., 2011) . Each cluster was annotated based on the Ensembl (release 72) gene annotation information by applying BEDTools' intersectBed (version 2.16.2) (Quinlan and Hall, 2010) .
Motif Identification among Clusters
